|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MT2A |
Gene summary for MT2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MT2A | Gene ID | 4502 |
| Gene name | metallothionein 2A | |
| Gene Alias | MT-2 | |
| Cytomap | 16q13 | |
| Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | P02795 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4502 | MT2A | GSM4909277 | Human | Breast | Precancer | 7.29e-11 | 9.12e-01 | 0.0177 |
| 4502 | MT2A | GSM4909285 | Human | Breast | IDC | 6.52e-14 | -6.14e-01 | 0.21 |
| 4502 | MT2A | GSM4909294 | Human | Breast | IDC | 1.49e-04 | 2.32e-01 | 0.2022 |
| 4502 | MT2A | GSM4909296 | Human | Breast | IDC | 3.86e-04 | -2.13e-01 | 0.1524 |
| 4502 | MT2A | GSM4909297 | Human | Breast | IDC | 2.02e-14 | 3.81e-01 | 0.1517 |
| 4502 | MT2A | GSM4909299 | Human | Breast | IDC | 1.79e-06 | 3.90e-01 | 0.035 |
| 4502 | MT2A | GSM4909308 | Human | Breast | IDC | 2.11e-08 | -4.87e-01 | 0.158 |
| 4502 | MT2A | GSM4909309 | Human | Breast | IDC | 1.47e-09 | 4.06e-01 | 0.0483 |
| 4502 | MT2A | GSM4909311 | Human | Breast | IDC | 5.75e-25 | 5.29e-02 | 0.1534 |
| 4502 | MT2A | GSM4909312 | Human | Breast | IDC | 9.38e-04 | -1.47e-01 | 0.1552 |
| 4502 | MT2A | GSM4909319 | Human | Breast | IDC | 1.59e-40 | 1.90e-01 | 0.1563 |
| 4502 | MT2A | GSM4909321 | Human | Breast | IDC | 6.37e-17 | -5.57e-01 | 0.1559 |
| 4502 | MT2A | ctrl6 | Human | Breast | Precancer | 8.04e-04 | 3.42e-01 | -0.0061 |
| 4502 | MT2A | brca1 | Human | Breast | Precancer | 8.78e-14 | -6.04e-01 | -0.0338 |
| 4502 | MT2A | brca2 | Human | Breast | Precancer | 1.44e-29 | 5.24e-01 | -0.024 |
| 4502 | MT2A | brca3 | Human | Breast | Precancer | 7.33e-50 | 7.14e-01 | -0.0263 |
| 4502 | MT2A | brca7 | Human | Breast | Precancer | 2.31e-04 | 6.79e-01 | -0.009 |
| 4502 | MT2A | brca10 | Human | Breast | Precancer | 4.26e-02 | 3.27e-01 | -0.0029 |
| 4502 | MT2A | M1 | Human | Breast | IDC | 5.08e-03 | -3.95e-01 | 0.1577 |
| 4502 | MT2A | M5 | Human | Breast | IDC | 4.73e-02 | -6.86e-01 | 0.1598 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00100389 | Breast | Precancer | response to metal ion | 47/1080 | 373/18723 | 3.88e-07 | 1.79e-05 | 47 |
| GO:00987548 | Breast | Precancer | detoxification | 24/1080 | 152/18723 | 6.49e-06 | 1.81e-04 | 24 |
| GO:00466868 | Breast | Precancer | response to cadmium ion | 14/1080 | 68/18723 | 2.74e-05 | 6.21e-04 | 14 |
| GO:00096368 | Breast | Precancer | response to toxic substance | 31/1080 | 262/18723 | 1.18e-04 | 2.12e-03 | 31 |
| GO:00550767 | Breast | Precancer | transition metal ion homeostasis | 20/1080 | 138/18723 | 1.28e-04 | 2.24e-03 | 20 |
| GO:00469165 | Breast | Precancer | cellular transition metal ion homeostasis | 17/1080 | 115/18723 | 3.15e-04 | 4.49e-03 | 17 |
| GO:00712767 | Breast | Precancer | cellular response to cadmium ion | 9/1080 | 40/18723 | 3.69e-04 | 5.03e-03 | 9 |
| GO:00712488 | Breast | Precancer | cellular response to metal ion | 24/1080 | 197/18723 | 4.35e-04 | 5.79e-03 | 24 |
| GO:00712418 | Breast | Precancer | cellular response to inorganic substance | 26/1080 | 226/18723 | 6.23e-04 | 7.78e-03 | 26 |
| GO:00975017 | Breast | Precancer | stress response to metal ion | 5/1080 | 19/18723 | 3.73e-03 | 3.04e-02 | 5 |
| GO:00100435 | Breast | Precancer | response to zinc ion | 9/1080 | 58/18723 | 5.67e-03 | 4.08e-02 | 9 |
| GO:0072503 | Breast | Precancer | cellular divalent inorganic cation homeostasis | 42/1080 | 486/18723 | 5.91e-03 | 4.21e-02 | 42 |
| GO:001003814 | Breast | IDC | response to metal ion | 65/1434 | 373/18723 | 2.95e-10 | 3.42e-08 | 65 |
| GO:004668613 | Breast | IDC | response to cadmium ion | 19/1434 | 68/18723 | 4.97e-07 | 2.45e-05 | 19 |
| GO:000963613 | Breast | IDC | response to toxic substance | 44/1434 | 262/18723 | 6.33e-07 | 3.00e-05 | 44 |
| GO:009875413 | Breast | IDC | detoxification | 29/1434 | 152/18723 | 3.97e-06 | 1.43e-04 | 29 |
| GO:007127613 | Breast | IDC | cellular response to cadmium ion | 11/1434 | 40/18723 | 1.48e-04 | 2.60e-03 | 11 |
| GO:005507613 | Breast | IDC | transition metal ion homeostasis | 23/1434 | 138/18723 | 3.20e-04 | 4.79e-03 | 23 |
| GO:001004311 | Breast | IDC | response to zinc ion | 13/1434 | 58/18723 | 3.59e-04 | 5.18e-03 | 13 |
| GO:004691612 | Breast | IDC | cellular transition metal ion homeostasis | 20/1434 | 115/18723 | 4.35e-04 | 5.90e-03 | 20 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0497812 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
| hsa0497813 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
| hsa0497821 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
| hsa0497831 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
| hsa0497814 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
| hsa0497815 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
| hsa049782 | Stomach | CAG with IM | Mineral absorption | 12/640 | 60/8465 | 1.52e-03 | 1.01e-02 | 7.10e-03 | 12 |
| hsa049783 | Stomach | CAG with IM | Mineral absorption | 12/640 | 60/8465 | 1.52e-03 | 1.01e-02 | 7.10e-03 | 12 |
| hsa049784 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
| hsa049785 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
| hsa049786 | Stomach | CAG | Mineral absorption | 8/368 | 60/8465 | 4.18e-03 | 2.94e-02 | 2.36e-02 | 8 |
| hsa049787 | Stomach | CAG | Mineral absorption | 8/368 | 60/8465 | 4.18e-03 | 2.94e-02 | 2.36e-02 | 8 |
| hsa049788 | Stomach | SIM | Mineral absorption | 11/465 | 60/8465 | 3.61e-04 | 3.41e-03 | 2.74e-03 | 11 |
| hsa049789 | Stomach | SIM | Mineral absorption | 11/465 | 60/8465 | 3.61e-04 | 3.41e-03 | 2.74e-03 | 11 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MT2A | SNV | Missense_Mutation | c.17N>T | p.Ser6Phe | p.S6F | P02795 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |
| MT2A | SNV | Missense_Mutation | c.41N>T | p.Thr14Ile | p.T14I | P02795 | protein_coding | tolerated(0.13) | benign(0.121) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MT2A | SNV | Missense_Mutation | rs149120520 | c.158C>T | p.Ala53Val | p.A53V | P02795 | protein_coding | deleterious(0.04) | benign(0.14) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| MT2A | SNV | Missense_Mutation | novel | c.161C>T | p.Ser54Leu | p.S54L | P02795 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MT2A | SNV | Missense_Mutation | novel | c.28N>T | p.Gly10Cys | p.G10C | P02795 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4502 | MT2A | NA | PARACETAMOL | ACETAMINOPHEN | 9570328 | |
| 4502 | MT2A | NA | ETHANOL | ALCOHOL | 1733046 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |